scholarly journals BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study

2015 ◽  
Vol 24 (6) ◽  
pp. 881-888 ◽  
Author(s):  
Hildegunn Høberg-Vetti ◽  
Cathrine Bjorvatn ◽  
Bent E Fiane ◽  
Turid Aas ◽  
Kathrine Woie ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Genetic Counselling ◽  
Newly Diagnosed ◽  
Breast And Ovarian Cancer

Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden.

1998 ◽  
Vol 16 (2) ◽  
pp. 397-404 ◽  
Author(s):  
O T Jóhannsson ◽  
J Ranstam ◽  
A Borg ◽  
H Olsson
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Matched Control ◽  
Brca1 Mutation ◽  
Population Based ◽  
Control Group ◽  
Breast And Ovarian Cancer ◽  
Population Based Study ◽  
Matched Control Group ◽  
Group Survival

PURPOSE Recent studies indicate that BRCA1 breast and ovarian tumors may have an advantageous survival. In this population-based study, the survival of carriers of a mutated BRCA1 gene was investigated. PATIENTS AND METHODS The survival of 71 BRCA1-associated cancer patients (33 breast cancer, seven breast and ovarian cancer, and 31 ovarian cancer patients from 21 families with BRCA1 germline mutations) diagnosed after 1958 was compared with that of a population-based comparison group that consisted of all other invasive breast (n = 28,281) and ovarian (n = 7,011) cancers diagnosed during 1958 to 1995, as well as an age- and stage-matched control group. RESULTS No apparent survival advantage was found for BRCA1-associated breast cancers upon direct comparison. After adjustment for age and calendar year of diagnosis, survival was equal to or worse than that of the comparison group (hazards ratio [HR], 1.5; 95% confidence interval [CI], 0.9 to 2.4). In comparison with an age- and stage-matched control group, survival again appeared equal or worse (HR, 1.5; 95% CI, 0.6 to 3.7). For BRCA1-associated ovarian cancers, an initial survival advantage was noted that disappeared with time. Due to this time dependency, multivariate analyses cannot adequately be analyzed. Compared with the age- and stage-matched control group, survival again appeared equal or worse (HR, 1.2; 95% CI, 0.5 to 2.8). CONCLUSION The results suggest that survival for carriers of a BRCA1 mutation may be similar, or worse than, that for breast and ovarian cancer in general. This finding is in accordance with the adverse histopathologic features observed in BRCA1 tumors and underlines the need for surveillance in families that carry a BRCA1 mutation.

scholarly journals High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area

2005 ◽  
Vol 7 (5) ◽  
Author(s):  
Petr Pohlreich ◽  
Michal Zikan ◽  
Jana Stribrna ◽  
Zdenek Kleibl ◽  
Marketa Janatova ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Brca1 Gene ◽  
Germline Mutations ◽  
Breast And Ovarian Cancer

Mutations in the BRCA1 gene in it alian breast and ovarian cancer patients

1997 ◽  
Vol 33 ◽  
pp. S9
Author(s):  
L. Ottini ◽  
C. D’Amico ◽  
C. Noviello ◽  
C. Pizzi ◽  
S. Lauro ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Brca1 Gene ◽  
Breast And Ovarian Cancer

scholarly journals Recurrent moderate‐risk mutations in Finnish breast and ovarian cancer patients

2019 ◽  
Vol 145 (10) ◽  
pp. 2692-2700 ◽  
Author(s):  
Anna Nurmi ◽  
Taru A. Muranen ◽  
Liisa M. Pelttari ◽  
Johanna I. Kiiski ◽  
Tuomas Heikkinen ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Breast And Ovarian Cancer ◽  
Moderate Risk

Mutation screening of Bulgarian hereditary breast and ovarian cancer patients with multi-gene cancer panel

2016 ◽  
Vol 61 ◽  
pp. S37
Author(s):  
A. Mitkova ◽  
R. Dodova ◽  
D. Pencheva ◽  
A. Vlahova ◽  
M. Taushanova-Hadjieva ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Cancer Patients ◽  
Mutation Screening ◽  
Breast And Ovarian Cancer ◽  
Cancer Panel
Sign in / Sign up

Export Citation Format

Share Document